SK bioscience Initiates International Phase 1/2 Clinical Trial of Universal Vaccine Candidate Targeting Sarbecovirus Family
Global phase 1/2 clinical trial initiated for GBP511, a vaccine targeting the Sarbecovirus Family Next-generation vaccine leveraging SKYCovione's recombinant protein-based platform and nanoparticle technology SK bioscience will continue to...